252 related articles for article (PubMed ID: 9933143)
1. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
Ongini E; Dionisotti S; Gessi S; Irenius E; Fredholm BB
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):7-10. PubMed ID: 9933143
[TBL] [Abstract][Full Text] [Related]
2. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA
J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.
Merighi S; Varani K; Gessi S; Cattabriga E; Iannotta V; Ulouglu C; Leung E; Borea PA
Br J Pharmacol; 2001 Nov; 134(6):1215-26. PubMed ID: 11704641
[TBL] [Abstract][Full Text] [Related]
4. Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.
Ji XD; Jacobson KA
Drug Des Discov; 1999 Nov; 16(3):217-26. PubMed ID: 10624567
[TBL] [Abstract][Full Text] [Related]
5. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
Zocchi C; Ongini E; Ferrara S; Baraldi PG; Dionisotti S
Br J Pharmacol; 1996 Apr; 117(7):1381-6. PubMed ID: 8730729
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
Yang M; Soohoo D; Soelaiman S; Kalla R; Zablocki J; Chu N; Leung K; Yao L; Diamond I; Belardinelli L; Shryock JC
Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):133-44. PubMed ID: 17310264
[TBL] [Abstract][Full Text] [Related]
8. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.
Hayallah AM; Sandoval-Ramírez J; Reith U; Schobert U; Preiss B; Schumacher B; Daly JW; Müller CE
J Med Chem; 2002 Mar; 45(7):1500-10. PubMed ID: 11906291
[TBL] [Abstract][Full Text] [Related]
9. Activation of multiple sites by adenosine analogues in the rat isolated aorta.
Prentice DJ; Hourani SM
Br J Pharmacol; 1996 Jul; 118(6):1509-17. PubMed ID: 8832079
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition.
Lopes LV; Cunha RA; Kull B; Fredholm BB; Ribeiro JA
Neuroscience; 2002; 112(2):319-29. PubMed ID: 12044450
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
Klotz KN; Hessling J; Hegler J; Owman C; Kull B; Fredholm BB; Lohse MJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):1-9. PubMed ID: 9459566
[TBL] [Abstract][Full Text] [Related]
12. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
[TBL] [Abstract][Full Text] [Related]
13. [3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies.
Fredholm BB; Lindström K; Dionisotti S; Ongini E
J Neurochem; 1998 Mar; 70(3):1210-6. PubMed ID: 9489743
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.
Gessi S; Varani K; Merighi S; Morelli A; Ferrari D; Leung E; Baraldi PG; Spalluto G; Borea PA
Br J Pharmacol; 2001 Sep; 134(1):116-26. PubMed ID: 11522603
[TBL] [Abstract][Full Text] [Related]
15. Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors.
Varani K; Cacciari B; Baraldi PG; Dionisotti S; Ongini E; Borea PA
Life Sci; 1998; 63(5):PL 81-7. PubMed ID: 9714428
[TBL] [Abstract][Full Text] [Related]
16. Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A(2A) receptors.
Fredholm BB; Lindström K
Eur J Pharmacol; 1999 Sep; 380(2-3):197-202. PubMed ID: 10513579
[TBL] [Abstract][Full Text] [Related]
17. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.
Poucher SM; Keddie JR; Singh P; Stoggall SM; Caulkett PW; Jones G; Coll MG
Br J Pharmacol; 1995 Jul; 115(6):1096-102. PubMed ID: 7582508
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of adenosine A2B receptors: studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes.
Feoktistov I; Biaggioni I
Biochem Pharmacol; 1998 Mar; 55(5):627-33. PubMed ID: 9515573
[TBL] [Abstract][Full Text] [Related]
19. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.
Gao ZG; Kim SG; Soltysiak KA; Melman N; IJzerman AP; Jacobson KA
Mol Pharmacol; 2002 Jul; 62(1):81-9. PubMed ID: 12065758
[TBL] [Abstract][Full Text] [Related]
20. Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices.
Latini S; Bordoni F; Corradetti R; Pepeu G; Pedata F
Br J Pharmacol; 1999 Nov; 128(5):1035-44. PubMed ID: 10556941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
